Background {#Sec1}
==========

Awake craniotomy is commonly performed for resection of epileptic lesions or tumors located close to or into the functionally essential motor, cognitive, or sensory cortical areas \[[@CR1]\]. It allows continuous monitoring of patients' neurological functions throughout the surgery to minimize iatrogenic language or motor deficits. However, this technique brings challenges both to the neurosurgeon and anesthesiologist. The anesthetic management for this type of surgery must include sedation, analgesia, respiratory and hemodynamic control, and a responsive, co-operative patient for neurologic testing intra-operatively. There is a growing trend of preference for awake craniotomy as the approach for the removal of tumors in the sensitive cortical area has been established over the last few decades.

Airway management in the anesthesia for awake craniotomy is always concerned by anesthesiologists. Up to date, a series of venting devices including nasal cannula \[[@CR2]\], simple facemask \[[@CR3]\], bilateral nasopharyngeal \[[@CR4]\], laryngeal mask \[[@CR5]\], and endotracheal tube \[[@CR6]\] have been used in the awake craniotomy. When these methods were applied, the patient's head is fixed during the surgical procedure, and potential laryngospasm or cough occur when the patient is awake, which may result in surgical bleeding, increased intracranial pressure or neurological injury. Thus, endotracheal intubation or laryngeal mask, and a deeper grade of sedation/anesthesia (BIS value at 40--60) are required for the patients to prevent coughing and laryngospasm. Consequently, it takes a longer time for the patient to recover from anesthesia. Furthermore, it is difficult to re-establish the airway when the patient is inducted into the state of being asleep again \[[@CR6]--[@CR8]\]. The spontaneous breathing can be maintained under mild to moderate sedation (BIS value 60--80) through nasopharynx or oropharyngeal airways. However, nasopharyngeal or oropharyngeal airways could not completely relieve upper airway obstruction, and concentration of inhaled oxygen cannot be adjusted. In addition, nasopharyngeal airway may cause injury to nasopharynx, and the airway may be obstructed by secretions or blood clot. Furthermore, some patients may have difficulty in tolerating the nasopharyngeal or oropharyngeal airways or feel uncomfortable due to the dry airway.

Currently, while there is still no consensus or any established protocol for the best airway management for awake craniotomy, in recent years, a novel oxygen supply device, a high-flow nasal cannula (HFNC), has been introduced into medical practice \[[@CR9]--[@CR11]\]. HFNC is capable of delivering humidified (100% humidity) and heated (37 °C) oxygen at a maximum flow rate of 60 L/min \[[@CR11], [@CR12]\]. HFNC has presented many potential advantages over traditional oxygen supply devices, including decreased nasopharyngeal resistance, washing out of the nasopharyngeal dead space, generation of positive pressure in the pharynx, increasing alveolar recruitment in the lungs, humidification of the airways, increased fraction of inspired oxygen and improved mucociliary clearance \[[@CR13]--[@CR18]\]. Emerging evidence indicates that HFNC is effective in various clinical settings, such as acute respiratory failure \[[@CR11], [@CR19], [@CR20]\], acute heart failure \[[@CR21], [@CR22]\], postoperative hypoxemia after cardiac surgery \[[@CR23], [@CR24]\], during sedation and analgesia \[[@CR25]\]. However, there is no published study on the investigation of clinical efficacy and safety of HFNC in patients undergoing awake craniotomy. Therefore, we designed this study to evaluate the clinical outcomes of HFNC by comparing HFNC with NPA in the anesthesia management for awake craniotomy. The primary endpoint of this study was to determine if HFNC could be safely used during awake craniotomy, and secondary endpoint was to determine if HFNC is superior to the traditional NPA in terms of outcomes and safety in the awake craniotomy.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

We collected medical data of patients who underwent awake craniotomy at our hospital from June 2018 to July 2019. This manuscript adheres to the applicable CONSORT guidelines. This clinical trial was approved by the Institutional Ethics Committee (approval number: KY2018--232) and registered at <http://www.chictr.org.cn/index.aspx> (registration number: CHiCTR1800016621).

The inclusion criteria: 1). Patients were 14--70 years of age. No gender preference; 2). Intracranial tumors or epileptic lesions located in the eloquent brain areas and its peripheral areas, wake-up anesthesia was required in craniotomy; 3). American Society of Anesthesiologists (ASA) physical status: Grade I or II; 4). Patients had no aphasia or changes in muscle strength before surgery.

The exclusion criteria: 1). Patients had severe organ diseases and were in decompensation (such as medical severe complications: a. Cardiac functional capacity ≥ class III; b. Respiratory failure; c. Hepatic and renal dysfunction; d. Hematological diseases; e. Uncontrolled hypertension; f. Patients with a history of COPD, pulmonary fibrosis, or long-term heavy smoking before surgery; g. Patients with severe intracranial hypertension, or even had cerebral herniation before surgery); 2). Patients who were extremely fear of surgery and were expected to have difficulty in cooperating during the operation; 3). Patients with conscious or cognitive dysfunction before surgery; 4). Patients who were unable to communicate well before surgery; 5). Patients with morbid obesity (BMI ≥ 40) accompanied by obstructive sleep apnea syndrome; 6). Patients had difficult airways; 7). Patients suffered from glioma along with other tumors outside the nervous system; 8). Pregnant women; 9). Patients involved in other clinical trials in the past three months.

Sixty-five patients were eventually enrolled in this study. They were randomly assigned into the following three groups according to the airway management during anesthesia: Group 1 (*n* = 22), patients used HFNC device with an oxygen flow rate of 40 L/min (HFNC 40); Group 2 (*n* = 20), patients used HFNC device with an oxygen flow rate of 60 L/min (HFNC 60); Group 3 (*n* = 23), patients used nasopharyngeal airway (NPA). Patients were evaluated during the pre-operative visit by the anesthesiologist and the procedure was explained in detail.

Anesthesia management {#Sec4}
---------------------

In the operating room, the peripheral intravenous catheters were set up, and standard monitors such as electrocardiograph, pulse oximeter, and non-invasive blood pressure measurement devices were connected. Invasive blood pressure was monitored after arterial cannulation with local antiesthetic (LA) infiltration in radial or dorsalis pedis artery. Bispectral index (BIS®) monitoring (A-2000; Aspect Medical Systems, Newton, MA, USA) was connected to titrate the amount of sedatives and hypnotics. Sedative drugs were injected by a pump in the following sequence: 1). A loading dose of 0.6 μg/kg dexmedetomidine was infused within 15 min. Then, dexmedetomidine was maintained at 0.1 μg/kg/h. 2). Remifentanil Target controlled Infusion model (TCI) (Ce) was maintained at 0.5--2.0 ng/ml, which started from 0.5 μg and increased by 0.5 μg every 5--10 min till respiration frequence was at least 12 times/min. When respiration was nearly 12 times/min, TCI increased by 0.25 μg till stabilized. After the scalp nerve was blocked with 20 mL of 0.75% ropivacaine + 10 mL of 2% lidocaine + 1: 200,000 of epinephrine, propofol was infused under TCI (Ce) model at the dose of 1.0--2.0 μg/ml. Specifically, titration target of propofol was to reach BIS: 60--70, and respiration frequency: 10--20 times/min. Propofol TCI was set to 1.0--2.0 μg/mL, which started from 1.0 μg and increased by 0.5 μg every 10--15 min till BIS reached 70. If BIS decreased to 60, TCI concentration increased by 0.25 μg till stabilized. Three ways of oxygen delivery were established. 1). Group I- HFNC 40, high-flow nasal cannula (HFNC) device was used, and oxygen flow rate was set at 40 L/ min, FiO~2~ 60%, airway humidified temperature was set at 34°C; 2). Group II- HFNC 60, high-flow nasal cannula (HFNC) device was used, and oxygen flow rate was set at 60 L/ min; FiO~2~ 60%, airway humidified temperature was set at 34°C; 3). Group III-nasopharyngeal airway (NPA): nasopharynx airway device was used. The end of the nasopharyngeal airway was connected to the threaded tube of anesthesia machine. The oxygen flow rate was set at 6 L/min, FiO~2~ 60% with no humidification.

When BIS value was maintained at 60--70 and the respiratory rate was maintained at 12--20 times/min by titration of propofol and remifentanil, induction of anesthesia was considered as completed. A urinary catheter was inserted. The head of the patient was fixed with a Mayfield head clamp. The body was adjusted to a comfortable position; with the head slightly elevated in order to avoid jugular venous flow compression. Such position prevents airway occlusion when the patient was asleep. The patient was asleep during the processes of scalp incision, bone flap removal, and dura suspending. Before bone flap removal, mannitol was administrated at the dose of 1.0 g/kg for 20 min. The intracranial pressure was assessed by the surgeons five seconds after removing the bone flap using Brain Relaxation Score (BRS). Specifically, by palpating and feeling the tension of the dura mater, BRS was subjectively scored by the surgeons from 1 to 10, with 10 was the most satisfied intracranial pressure control. After the dura suspending was done, propofol infusion was stopped, and the patient was allowed to wake up spontaneously. If the patient could not be awoken in 10 min after stopping propofol infusion, dexmedetomidine infusion would be decreased or stopped. After the BIS value was maintained above 90, cortical functional mapping was achieved using NIM-ECLIPSE® System (Medtronic Xomed Inc., Jacksonville, FL, USA) with a monopolar probe, delivering stimuli with a single 1 ms pulse with a 60 Hz frequency during surgical tumor resection. Upon the requirement of surgeons, the deep sedation was induced again by the titration of propofol, dexmedetomidine, and remifentanil. BIS value at 60--70 and the respiratory rate at 12--20 times/min could be considered as the completion of re-induction of anesthesia.

Study variables {#Sec5}
---------------

The baseline characteristics including age, gender, body mass index (BMI) and ASA physical status was collected. The following intraoperative data were collected: 1). Blood gas analysis at 6 different time points (before induction of anesthesia; 15 min after induction of anesthesia, 15 min after the adjustment of comfortable body position, dura suspension was completed, functional mapping was being performed, 15 min after re-induction of anesthesia). 2). Vital signs (heart rate, blood pressure, SpO~2~, and respiratory rate were measured every 5 min). 3). Depth of sedation/anesthesia (BIS value and OAA/S score). 4). Brain Relaxation Score, which was assessed every 15 min. 5). The time that patients took to wake up spontaneously. 6). The total time that patients were awake. 7). Total dose of each sedative drug. 8). Total anesthesia time. 9). Gastric antral volume before and after surgery. 10). Incidence of adverse events. The gastric antral volume was evaluated by measuring the cross-sectional area (CSA) of the antrum using the ultrasound \[[@CR26]\]. The head to sacral (CC) and anteroposterior (AP) diameter of the antrum was measured. The CSA was calculated by the formula CSA = AP x CC x π/4.

Adverse events {#Sec6}
--------------

Information of the following adverse events was collected. 1). The incidence of respiratory tract obstruction, which was defined as no airflow, apnea, or snoring due to partial airway obstrction. 2). Airway injury, which was defined as blood or bloody secretion found on the tube of NPA or in the patients' mouth. 3). Increased intracranial pressure that required instant treatment.

Statistical analysis {#Sec7}
--------------------

The sample size was calculated using PASS11 software. By ANOVA, took SPO~2~ as major parameter, that is, gave SPO~2~ as 100, 95, and 97 for HFNC 40, HFNC 60 and NPA, respectively, and a was 0.05. Sample number was from 5 to 40 with 5 as interval, and standard deviations were 2, 4, and 5. Statistical power and sample size were then calculated. When sample number was 20 and SD was 5, 0.8 of the statistical power was obtained; if SD was 2, 1 statistical power was obtained. Therefore, 20 was chosen as the sample size of each group.

The categorical variables were expressed as the frequency (%), and the Chi-square test was used for comparison. The measurable variables were expressed as mean ± SD, representation or median (interquartile range). Differences between groups were compared using One-way ANOVA when normal distribution was achieved, followed by Student-Newman-Keuls (SNK) test. If the normal distribution was not achieved, the Kruskal-Wallis test was used. Comparison within group, that is, before and after operation, was performed by Paired Student *t* test. All tests were two-tailed and statistical significance was accepted at *P* \<  0.05. All statistical analysis was performed with SAS 9.2.

Results {#Sec8}
=======

Baseline characteristics {#Sec9}
------------------------

This study enrolled 65 patients who underwent awake craniotomy and supplied oxygen via HFNC or NPA. Baseline characteristics of patients were presented in Table [1](#Tab1){ref-type="table"}. There was no significant difference in age, gender ratio, BMI, presence of epilepsy or hypertension, and types of surgery among three groups (Table [1](#Tab1){ref-type="table"}). Table 1Baseline characteristics of the participantsVariablesIndex of variablesHFNC 40\
(*n* = 22)HFNC 60\
(*n* = 20)NPA\
(*n* = 23)Age (years)Mean ± SD37.32 ± 15.2841.25 ± 13.8940.43 ± 10.16Body Mass Index (kg/m^2^)Mean ± SD23.71 ± 3.6823.45 ± 4.1621.81 ± 2.29GenderMale11 (50.00)13 (65.00)11 (47.83)Female11 (50.00)7 (35.00)12 (52.17)ASA physical statusI10 (45.45)11 (55.00)16 (69.57)II12 (54.55)9 (45.00)7 (30.43)EpilepsyNo18 (81.82)18 (90.00)18 (78.26)Yes4 (18.18)2 (10.00)5 (21.74)HypertensionNo20 (90.91)19 (95.00)23 (100.0)Yes2 (9.09)1 (5.00)0 (0.00)Surgery typeOther surgery4 (18.18)1 (5.00)2 (8.70)Right-sided glioma resection7 (31.82)2 (10.00)7 (30.43)Left-sided glioma resection11 (50.00)17 (85.00)14 (60.87)*HFNC* high-flow nasal cannula, *NPA* nasopharyngeal airway, *ASA* American Society of Anesthesiologists

Intraoperative data of the patients using HFNC or NPA devices {#Sec10}
-------------------------------------------------------------

### Blood gas analysis {#Sec11}

There were no significant differences in SpO~2~ and PaCO~2~ at various time points during surgery among HFNC 40, HFNC 60 and NPA groups (Table [2](#Tab2){ref-type="table"}). However, patients using HFNC 40 or HFNC 60 treatment achieved higher PaO~2~/FiO~2~ than patients using the nasopharyngeal airway at various time points (HFNC 40 vs. NPA or HFNC 60 vs. NPA, all *P* \<  0.05, Table [2](#Tab2){ref-type="table"}). In addition, in this study, mild to moderate sedation generated high but acceptable PaCO~2~ level in all three groups at the end of dura suspension although the differences of PaCO~2~ before and after the anesthesia were significant in all three groups (HFNC 40: 10.80 ± 4.40; HFNC 60: 10.60 ± 3.91; NPA: 12.25 ± 5.10, *P* \<  0.01, Table [3](#Tab3){ref-type="table"}). Table 2Intraoperative blood gas analysis among three groupsVariablesSample collection time pointHFNC 40\
(*n* = 22)HFNC 60\
(*n* = 20)NPA\
(*n* = 23)SpO~2~Before induction of anesthesia98.2 ± 1.497.4 ± 2.097.5 ± 1.215 min after induction of anesthesia99.4 ± 1.099.6 ± 0.599.8 ± 0.415 min after achieving position99.6 ± 0.799.5 ± 0.699.7 ± 0.6End of dura suspension99.6 ± 0.799.6 ± 0.599.8 ± 0.4Cortical functional mapping99.5 ± 0.899.8 ± 0.399.9 ± 0.215 min after re-induction99.7 ± 0.799.6 ± 0.699.7 ± 0.5PaCO~2~Before induction of anesthesia39.4 ± 3.738.6 ± 4.739.5 ± 4.915 min after induction of anesthesia46.2 ± 4.645.8 ± 7.349.6 ± 6.615 min after achieving position48.0 ± 4.347.9 ± 6.350.7 ± 6.2End of dura suspension50.2 ± 4.149.2 ± 6.151.7 ± 6.2Cortical functional mapping44.1 ± 2.842.3 ± 4.943.6 ± 5.915 min after re-induction47.0 ± 4.346.0 ± 5.048.3 ± 5.4PaO~2~/FiO~2~Before induction of anesthesia451.8 ± 69.4421.9 ± 112.7447.8 ± 64.915 min after induction of anesthesia475.5 ± 81.7496.00 ± 80.54332.1 ± 115.0^\*\#^15 min after achieving position500.5 ± 93.6499.45 ± 73.21376.9 ± 92.1^\*\#^End of dura suspension477.6 ± 103.8464.2 ± 90.8384.3 ± 98.6^\*\#^Cortical functional mapping475.0 ± 106.1465.4 ± 78.0275.1 ± 92.8^\*\#^15 min after re-induction488.1 ± 100.4494.7 ± 81.0315.6 ± 93.9^\*\#^Data were expressed as mean ± SD. \**P* \< 0.05 compared with HFNC 40 group; ^\#^*P* \< 0.05 compared with HFNC 60 group. HFNC: high-flow nasal cannula; NPA: nasopharyngeal airwayTable 3PaCO~2~ alteration at the end of dura suspension compared to before surgeryGroupSample\
NumberDifference\
(Mean ± SD)Median\
(Interquartile range)*P* valueHFNC 402210.80 ± 4.4010.75 (6.50,13.90)\< 0.001^a^HFNC 602010.60 ± 3.9111.00 (6.95,12.85)\< 0.001^a^NPA2312.25 ± 5.1012.50 (8.10,14.90)\< 0.001^aa^Compared to the value before surgery. HFNC: high-flow nasal cannula*NPA* nasopharyngeal airway

### Brain relaxation score and gastric antral volume {#Sec12}

There were no differences in Brain Relaxation Score at the end of the dura suspension and during the period of cortical functional mapping among the three groups (Table [4](#Tab4){ref-type="table"}). Furthermore, no differences were noted in gastric antral volume among the three groups as well as before and after operation in any of the three groups (Table [4](#Tab4){ref-type="table"}). Table 4Brain Relaxation Score and gastric antral volume among three groupsGroupBrain Relaxation ScoreGastric antral volume (L)End of dura suspensionFunctional mappingPreoperativePostoperativeHFNC 40 (*n* = 22)7.9 ± 1.68.6 ± 0.81.6 ± 0.92.0 ± 0.4HFNC 60 (*n* = 20)7.3 ± 1.38.7 ± 2.11.7 ± 0.42.1 ± 0.4NPA(*n* = 23)7.0 ± 1.98.1 ± 1.11.6 ± 0.31.9 ± 0.4Data were expressed as mean ± SD. There was no significant difference in any pair of comparison. L: liter; HFNC: high-flow nasal cannula; NPA: nasopharyngeal airway

### Anesthesia duration, time that patients took to wake up and the time that patients maintained awake {#Sec13}

There were no differences in anesthesia duration and the time that patients took to wake up spontaneously among the three groups (Table [5](#Tab5){ref-type="table"}). However, the awake time maintained in the patients receiving HFNC 60 treatment (141.5 \[98.0, 198.5\]) was longer than that in the patients received HFNC 40 (105.0 \[75.0, 136.0\], *P* \<  0.05, Table [5](#Tab5){ref-type="table"}) or NPA treatment (99.0 \[85.0, 113.0\], *P* \<  0.05, Table [5](#Tab5){ref-type="table"}), respectively. Table 5Comparison of anesthesia duration, time that patients took to wake up and the time that patients maintained awakeVariablesHFNC 40 (n = 22)HFNC 60 (n = 20)NPA (*n* = 23)Anesthesia Duration (min)366.5 (300.0, 3933.0)380 (321.5407.5)385.0 (340.0,404.0)Time patients took towake up (min)8.0 (6.0,12.0)7.0 (6.0,11.0)8.0 (7.0,13.0)Awakening Duration (min)105.0 (75.0,136.0)141.5 (98.0,198.5) ^\*^99.0 (85.0,113.0) ^\#^Data were expressed as median (interquartile range). \**P* \< 0.05 compared with HFNC 40; ^\#^*P* \< 0.05 compared with HFNC 60. HFNC: high-flow nasal cannula; NPA: nasopharyngeal airway

### Total sedative drugs used by patients {#Sec14}

There were no differences in the total dose of dexmidiatomidine, propofol or remifentanil used throughout the whole surgery among the three groups (*P* \> 0.05, Table [6](#Tab6){ref-type="table"}). Table 6Total sedative medications used for the patientsMedicationsHFNC 40\
(*n* = 22)HFNC 60\
(*n* = 20)NPA\
(*n* = 23)Dexmediatomidine (μg)76.3 (67.6,83.2)80.5 (59.7102.4)82.0 (63.0,115.0)Remifentanil (mg)0.43 (0.35,0.48)0.39 (0.27,0.51)0.45 (0.36,0.56)Propofol (mg)403.5 (318.0,575.0)397.25 (340.0,608.0)442.0 (273.0,500.0)Data were expressed as median (interquartile range). HFNC: high-flow nasal cannula; NPA: nasopharyngeal airway

### Incidence of adverse events {#Sec15}

The incidence of respiratory tract obstruction in NPA group was 43% (10 out of 23 patients), which was significantly higher than that in HFNC 40 (3 out of 22 patients, 13%, *P* \<  0.05) or HFNC 60 group (1 out of 20 patients, 5%, *P* \< 0.05, Table [7](#Tab7){ref-type="table"}). No patient presented airway injury (blood or bloody secretion found on the tube of NPA or in the patients' mouth) in HFNC 40 or HFNC 60 group (Table [7](#Tab7){ref-type="table"}). However, 6 patients in the NPA group suffered from airway injury, which was significantly higher than that in the patients using HFNC (all *P* \< 0.05, Table [7](#Tab7){ref-type="table"}). Three patients in HFNC 40 group, five patients in HFNC 60 group, and six patients in NPA group presented increased Brain Relaxation Score, and appropriate treatment, including mannitol infusion, body position change (head high and feet low), or decreased dose of anesthesia drugs, was required to reduce intracranial pressure. There were no differences in the incidence of intracranial pressure enhancement among the three groups (*P* \> 0.05, Table [7](#Tab7){ref-type="table"}). Table 7Incidence of adverse events among three groupsAdverse eventsVariable levelHFNC 40 (*n* = 22)HFNC 60 (*n* = 20)NPA\
(*n* = 23)Obstruction of upper airwayNo19 (86.3)19 (95.0)13 (56.5)Yes3 (13.6)^\*^1 (5.0)^\*^10 (43.5)Airway injuryNo22 (100.0)20 (100.0)17 (73.9)Yes0 (0.0)^\*^0 (0.0)^\*^6 (26.1)Requiring treatment for increased Brain Relaxation ScoreNo19 (86.4)15 (75.0)17 (73.9)Yes3 (13.6)5 (25.0)6 (26.1)\**P* \< 0.05 compared with NPA. HFNC: high-flow nasal cannula; NPA: nasopharyngeal airway. "Obstruction of upper airway" was defined as no airflow, apnea or snoring due to partial airway obstruction. "Airway injury" was defined as blood or bloody secretion was found on the tube of NPA or in the patients' mouth

Discussion {#Sec16}
==========

To our knowledge, this was the first study evaluating the efficacy and safety of HFNC application in the anesthesia management for awake craniotomy. As compared with NPA group, HFNC 40 or HFNC 60 treatment resulted in similar physiological response including intraoperative SpO~2~ and PaCO~2~, Brain Relaxation Score at the end of dura suspension or during the period of cortical functional mapping, and the gastric antral volume before and after anesthesia. However, both HFNC 40 and HFNC 60 treatments achieved higher PaO~2~/FiO~2~ ratio than NPA did. Furthermore, neither HFNC 40 nor HFNC 60 treatment caused respiratory tract injury while NPA did cause the injury. In addition, less airway obstruction occurred in the patients given HFNC 40 or 60, and longer awake time was observed in the patients with HFNC 60.

In recent years, HFNC has become a world-wide popular strategy in clinical practice for the delivery of humidified and heated oxygen in the treatment of the critically ill patient who requires high inspiratory oxygen therapy \[[@CR9]\]. It has been reported that humidified high flow oxygen may benefit not only mucociliary clearance and mobilization of respiratory secretions \[[@CR27], [@CR28]\], but also increasing patient comfort and reducing mucus injury \[[@CR10], [@CR11], [@CR18], [@CR23], [@CR29], [@CR30]\]. Furthermore, it does not impede mobility, oral intake, or speaking \[[@CR31], [@CR32]\]. Consistent with these studies, in the current study, neither HFNC 40 nor HFNC 60 treatment resulted in airway injury, while 26% of patients in NPA group presented airway injury. Furthermore, patients given HFNC 40 or 60 presented lower incidence of airway obstruction as compared with patients given NPA. This advantage of HFNC may be due to the increased nasopharyngeal pressure generated by high flow oxygen. In support of this concept, a similar phenomenon was observed in McGinley's study \[[@CR33]\]. They reported that high flow oxygen alleviated obstructive apnea-hypopnea syndrome in 11 patients \[[@CR33]\]. This phenomenon could be associated with the enhanced nasopharyngeal pressure at the end of exhalation, which resulted in decreased airway subsidence and subsequently relieved respiratory obstruction \[[@CR15], [@CR34], [@CR35]\].

In this study, high flow oxygen generated acceptable PaCO~2~ and desired PaO~2~. Although three patients in the HFNC 40 group presented increased PaCO~2~, it dropped to normal range when the oxygen flow was increased to 60 L/min, indicating that HFNC could generate a certain degree of continuous positive airway pressure (CPAP)-like effect, which depended on both flow rate and mouth position (open versus closed) \[[@CR14]\]. Nevertheless, PaCO~2~ level was significantly increased in all three treatment groups at each checking time point without significant differences among the three groups, suggesting PaCO~2~ could be affected by multiple factors in addition to the oxygen flow amount, and thus, it should be closely monitored by the Anethesiologist during the process of awake craniotomy.

The intracranial pressure was assessed by surgeons subjectively and expressed as Brain Relaxation Score in this study. During the processes of dura suspending and tumor resection, Brain Relaxation Score in both HFNC groups was maintained at the level that surgeons desired to have, suggesting intracranial pressure was not significantly affected by high flow oxygen inhalation.

In this study, all patients maintained spontaneous breath throughout the surgical process. One of the adverse effects of high flow oxygen inhalation could be gastric discomfort. Therefore, gastric antral volumes before and after anesthesia were compared among the three groups. We found that gastric antral volume did not change after anesthesia in any of the study groups, suggesting that HFNC do not lead to gas accumulation in the stomach and cause gastric discomfort. Furthermore, none of the HFNC patient needed invasive airway device during the surgery. To maintain the patient's sedation depth during the surgery, doses of anesthetics were adjusted according to the BIS value and the OAA/S score, which was satisfied by the sugeons and met the requirement of anesthesia management.

We recommended that initial flow rate be set at 40 L/min, which could be increased during the operation, if the patient have upper airway obstruction or other complications. When the upper airway obstruction cannot be relieved by increasing the inspired flow or position adjustment, airway management device (such as nasopharynx or oropharyngeal airway) must be immediately applied.

Conclusion {#Sec17}
==========

The current study demonstrated that application of HFNC 40 or 60 during awake craniotomy resulted in higher ratio of PaO~2~/FiO2, longer awaken time (HFNC 60), but less airway injury or obstruction compared to that of NPA. These findings suggested that nasal high-flow oxygen inhalation device can be safely and effectively used in the anesthesia management for awake craniotomy. However, findings of the current study should be confirmed in the morbid obesity patients in the future.

HFNC

:   High-flow nasal cannula

LA

:   Local antiesthetic

BMI

:   Body mass index

CSA

:   The cross-sectional area

CPAP

:   Continuous positive airway pressure
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